<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg"/></p>
<p>LNK01006 是一种新一代中枢神经系统穿透药物。来源：MY STOCKERS/Shutterstock.com。</p>
<p>Formation Bio 已获得 LNK01006 的全球权利，除大中华区外，该药物是一种高度选择性的酪氨酸激酶 2 (TYK2) 抑制剂，来自 Lynk Pharmaceuticals。</p>
<p>这款新一代中枢神经系统穿透药物将由 Formation 新成立的子公司 Bleecker Bio 开发。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Aptose Biosciences Inc 的 Tuspetinib</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Kymera Therapeutics Inc 的 KT-413</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，接触到 36 个领先媒体平台上的专业人士。</p>
<p>了解更多</p>
<p>Lynk Pharmaceuticals 将获得 Bleecker 的少数股权，以及一次性付款和可能达到 6.05 亿美元的里程碑付款。</p>
<p>该交易还包括未来资产销售的分级版税。</p>
<p>总部位于美国的投资基金 Pacific Bridge 作为 Bleecker 的少数联合投资者参与其中。</p>
<p>该资产最近获得了美国食品和药物管理局 (FDA) 的研究新药 (IND) 批准，允许在美国开始首次人体试验。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报的信息</p>
<p>Formation 打算在 2026 年上半年开始 I 期临床试验，作为其扩展临床阶段资产组合战略的一部分。</p>
<p>LNK01006 提供对 TYK2 介导的细胞因子信号传导的选择性抑制，并具有针对中枢免疫系统调节的药理特征。</p>
<p>该疗法的药理特征可能允许探索在中枢或局部免疫通路被认为重要的适应症。</p>
<p>Formation Bio 首席商务官 David Steinberg 表示：“该资产代表了我们所称的 ‘已知新’ 战略的一个典范，即将经过验证的机制应用于高未满足需求的新领域。</p>
<p>“利用世界级的人类专业知识、强大的临床数据集和自主研发的先进 AI 工具，我们围绕临床风险降低的资产类别的新疗法应用开发了深厚的假设。”</p>
<p>Lynk Pharmaceuticals 是一家专注于发现和开发免疫学和炎症疾病药物的临床阶段公司。</p>
<p>Lynk Pharmaceuticals 首席执行官赵奎万表示：“我们很高兴与 Formation Bio 合作，将 LNK01006 推进临床。</p>
<p>“Formation 经验丰富的临床开发团队和 AI 驱动的能力提供了将该化合物的科学潜力转化为有意义的患者影响的理想环境。”</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>提名现已关闭，感谢所有参与的组织 - 你们的反应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>Imagene 的 肿瘤智能 (OI) 套件 获得了精准肿瘤学创新奖，因其改变了制药公司设计和运行肿瘤试验的方式。从 AI 驱动的生物标志物发现到更智能的患者分层，看看 Imagene 如何在癌症药物开发中缩短时间、降低成本和风险。</p>
<p>发现影响</p>

<p>Formation Bio 已获得 Lynk Pharma 的 TYK2 抑制剂 LNK01006 的全球权利，但不包括大中华区。该药物具有中枢神经系统穿透能力，将由 Formation 的子公司 Bleecker Bio 开发。Lynk 将获得 Bleecker 的少数股权、最高达 6.05 亿美元的预付款和里程碑付款，以及分级版税。该药物已获得 FDA 的 IND 批准，可以在美国进行临床试验。Formation 计划于 2026 年进行 I 期临床试验，旨在扩展其临床阶段的产品组合。Lynk 专注于免疫学和炎症性疾病</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg"/></p>
<p>LNK01006 is a next-generation CNS-penetrant. Credit: MY STOCKERS/Shutterstock.com.</p>
<div class="lb-trans"><p>LNK01006 是一种新一代中枢神经系统穿透药物。来源：MY STOCKERS/Shutterstock.com。</p>
</div><p>Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals.</p>
<div class="lb-trans"><p>Formation Bio 已获得 LNK01006 的全球权利，除大中华区外，该药物是一种高度选择性的酪氨酸激酶 2 (TYK2) 抑制剂，来自 Lynk Pharmaceuticals。</p>
</div><p>This next-generation central nervous system (CNS)-penetrant will be developed by Bleecker Bio, a newly established subsidiary of Formation.</p>
<div class="lb-trans"><p>这款新一代中枢神经系统穿透药物将由 Formation 新成立的子公司 Bleecker Bio 开发。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Aptose Biosciences Inc's Tuspetinib</h4>
<div class="lb-trans"><h4>NPVM: Aptose Biosciences Inc 的 Tuspetinib</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Kymera Therapeutics Inc's KT-413</h4>
<div class="lb-trans"><h4>NPVM: Kymera Therapeutics Inc 的 KT-413</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，接触到 36 个领先媒体平台上的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Lynk Pharmaceuticals will obtain a minority equity stake in Bleecker, along with an upfront payment and potential milestone payments that could reach $605m.</p>
<div class="lb-trans"><p>Lynk Pharmaceuticals 将获得 Bleecker 的少数股权，以及一次性付款和可能达到 6.05 亿美元的里程碑付款。</p>
</div><p>The deal also includes tiered royalties on any future sales of the asset.</p>
<div class="lb-trans"><p>该交易还包括未来资产销售的分级版税。</p>
</div><p>US-based investment fund Pacific Bridge is participating as a minority joint investor in Bleecker.</p>
<div class="lb-trans"><p>总部位于美国的投资基金 Pacific Bridge 作为 Bleecker 的少数联合投资者参与其中。</p>
</div><p>The asset recently received US Food and Drug Administration (FDA) investigational new drug (IND) clearance, allowing the commencement of first-in-human trials in the US.</p>
<div class="lb-trans"><p>该资产最近获得了美国食品和药物管理局 (FDA) 的研究新药 (IND) 批准，允许在美国开始首次人体试验。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报的信息</p>
</div><p>Formation intends to begin a Phase I trial in the first half of 2026, as part of its strategy to expand its portfolio of clinical-stage assets.</p>
<div class="lb-trans"><p>Formation 打算在 2026 年上半年开始 I 期临床试验，作为其扩展临床阶段资产组合战略的一部分。</p>
</div><p>LNK01006 offers selective inhibition of TYK2-mediated cytokine signalling and features a pharmacological profile tailored for central immune system modulation.</p>
<div class="lb-trans"><p>LNK01006 提供对 TYK2 介导的细胞因子信号传导的选择性抑制，并具有针对中枢免疫系统调节的药理特征。</p>
</div><p>The pharmacologic profile of the therapy may allow for the exploration of indications where central or compartmentalised immune pathways are considered important.</p>
<div class="lb-trans"><p>该疗法的药理特征可能允许探索在中枢或局部免疫通路被认为重要的适应症。</p>
</div><p>Formation Bio chief business officer David Steinberg stated: “This asset represents a prime example of what we call our ‘Known In New’ strategy of applying validated mechanisms to novel areas of high unmet need.</p>
<div class="lb-trans"><p>Formation Bio 首席商务官 David Steinberg 表示：“该资产代表了我们所称的 ‘已知新’ 战略的一个典范，即将经过验证的机制应用于高未满足需求的新领域。</p>
</div><p>“Leveraging world class human expertise, robust clinical data sets and homegrown, state-of the-art AI tools, we’ve developed deeply grounded hypotheses around novel therapeutic applications of clinically de-risked asset classes.”</p>
<div class="lb-trans"><p>“利用世界级的人类专业知识、强大的临床数据集和自主研发的先进 AI 工具，我们围绕临床风险降低的资产类别的新疗法应用开发了深厚的假设。”</p>
</div><p>Lynk Pharmaceuticals is a clinical-stage company focused on discovering and developing medicines for immunology and inflammatory diseases.</p>
<div class="lb-trans"><p>Lynk Pharmaceuticals 是一家专注于发现和开发免疫学和炎症疾病药物的临床阶段公司。</p>
</div><p>Lynk Pharmaceuticals CEO Zhao-Kui (ZK) Wan stated: “We are excited to partner with Formation Bio to advance LNK01006 into the clinic.</p>
<div class="lb-trans"><p>Lynk Pharmaceuticals 首席执行官赵奎万表示：“我们很高兴与 Formation Bio 合作，将 LNK01006 推进临床。</p>
</div><p>“Formation’s experienced clinical development team and AI-enabled capabilities provide the ideal environment to translate this compound’s scientific potential into meaningful patient impact.”</p>
<div class="lb-trans"><p>“Formation 经验丰富的临床开发团队和 AI 驱动的能力提供了将该化合物的科学潜力转化为有意义的患者影响的理想环境。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名现已关闭，感谢所有参与的组织 - 你们的反应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
<div class="lb-trans"><p>Imagene 的 肿瘤智能 (OI) 套件 获得了精准肿瘤学创新奖，因其改变了制药公司设计和运行肿瘤试验的方式。从 AI 驱动的生物标志物发现到更智能的患者分层，看看 Imagene 如何在癌症药物开发中缩短时间、降低成本和风险。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

Formation Bio 获得了 Lynk Pharma 的 TYK2 抑制剂的全球使用权